3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD).

          Methods: The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML ( n = 10) and MM ( n = 11) were assessed in comparison to corresponding CD4 + and CD8 + T cells and peripheral blood- (PB) derived γδ T cells from HDs ( n = 16) using multiparameter flow cytometry.

          Results: BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27 CD45RA ++ cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4 + T cell population, with expression levels that were similar to that on CD8 + effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1 +-, TIGIT +-, TIM-3 +, and CD39 + cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT.

          Conclusion: Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular and cellular insights into T cell exhaustion.

          In chronic infections and cancer, T cells are exposed to persistent antigen and/or inflammatory signals. This scenario is often associated with the deterioration of T cell function: a state called 'exhaustion'. Exhausted T cells lose robust effector functions, express multiple inhibitory receptors and are defined by an altered transcriptional programme. T cell exhaustion is often associated with inefficient control of persisting infections and tumours, but revitalization of exhausted T cells can reinvigorate immunity. Here, we review recent advances that provide a clearer molecular understanding of T cell exhaustion and reveal new therapeutic targets for persisting infections and cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The prognostic landscape of genes and infiltrating immune cells across human cancers.

            Molecular profiles of tumors and tumor-associated cells hold great promise as biomarkers of clinical outcomes. However, existing data sets are fragmented and difficult to analyze systematically. Here we present a pan-cancer resource and meta-analysis of expression signatures from ∼18,000 human tumors with overall survival outcomes across 39 malignancies. By using this resource, we identified a forkhead box MI (FOXM1) regulatory network as a major predictor of adverse outcomes, and we found that expression of favorably prognostic genes, including KLRB1 (encoding CD161), largely reflect tumor-associated leukocytes. By applying CIBERSORT, a computational approach for inferring leukocyte representation in bulk tumor transcriptomes, we identified complex associations between 22 distinct leukocyte subsets and cancer survival. For example, tumor-associated neutrophil and plasma cell signatures emerged as significant but opposite predictors of survival for diverse solid tumors, including breast and lung adenocarcinomas. This resource and associated analytical tools (http://precog.stanford.edu) may help delineate prognostic genes and leukocyte subsets within and across cancers, shed light on the impact of tumor heterogeneity on cancer outcomes, and facilitate the discovery of biomarkers and therapeutic targets.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

              Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T cell responses and have proven to be effective targets in the setting of chronic diseases where constitutive co-inhibitory receptor expression on T cells dampens effector T cell responses. Unfortunately, many patients still fail to respond to therapies that target CTLA-4 and PD-1. The next wave of co-inhibitory receptor targets that are being explored in clinical trials include Lag-3, Tim-3, and TIGIT. These receptors, although they belong to the same class of receptors as PD-1 and CTLA-4, exhibit unique functions, especially at tissue sites where they regulate distinct aspects of immunity. Increased understanding of the specialized functions of these receptors will inform the rational application of therapies that target these receptors to the clinic.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Med (Lausanne)
                Front Med (Lausanne)
                Front. Med.
                Frontiers in Medicine
                Frontiers Media S.A.
                2296-858X
                08 November 2021
                2021
                : 8
                : 763773
                Affiliations
                [1] 1Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf , Hamburg, Germany
                [2] 2Infectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany
                [3] 3University Cancer Center Hamburg (UCCH)-Biobank, Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf , Hamburg, Germany
                Author notes

                Edited by: Bernhard F. Gibbs, University of Oldenburg, Germany

                Reviewed by: Daria M. Potashnikova, Lomonosov Moscow State University, Russia; Michael Danilenko, Ben-Gurion University of the Negev, Israel

                *Correspondence: Walter Fiedler fiedler@ 123456uke.de

                This article was submitted to Pathology, a section of the journal Frontiers in Medicine

                †These authors have contributed equally to this work

                Article
                10.3389/fmed.2021.763773
                8606547
                34820398
                30f2cc21-56af-4acc-8621-37ec65f01077
                Copyright © 2021 Brauneck, Weimer, Schulze zur Wiesch, Weisel, Leypoldt, Vohwinkel, Fritzsche, Bokemeyer, Wellbrock and Fiedler.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 24 August 2021
                : 04 October 2021
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 69, Pages: 13, Words: 9527
                Funding
                Funded by: Erich und Gertrud Roggenbuck-Stiftung, doi 10.13039/100010124;
                Funded by: Dr. Mildred Scheel Stiftung f�r Krebsforschung, doi 10.13039/501100005973;
                Funded by: Deutsche Forschungsgemeinschaft, doi 10.13039/501100001659;
                Categories
                Medicine
                Original Research

                (vδ1) γδ t cells,tigit,pd-1,cd39,aml,myeloma
                (vδ1) γδ t cells, tigit, pd-1, cd39, aml, myeloma

                Comments

                Comment on this article